The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2020 | Multiple myeloma: ADCs and BiTEs
Hans Lee, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the current role of antibody-drug conjugates (ADCs) and bi-specific antibodies in multiple myeloma, including belantamab mafodotin, an antibody-drug conjugate, recently approved in the U.S by the FDA for the treatment of relapsed/refractory multiple myeloma and highlights the ocular toxicities associated with this therapy. Dr Lee also discusses bi-specific antibodies as an exciting, off-the-shelf approach to the treatment of multiple myeloma, including the BiTE, AMG-420, alnuctamab (CC-93269), and teclistamab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
